In the complaint, the Plaintiffs alleged that the sale and use of the company’s SEER (Saline Enhanced Electrosurgical Resection) fluid-assisted electrosurgical device infringed on a patent owned by Medtronic and licensed to Salient.

The settlement calls for Bovie to immediately exit the monopolar and bipolar saline-enhanced RF device business (including Bovie’s SEER and BOSS) worldwide, and to acknowledge the validity and enforceability of Medtronic’s patent in the US and Europe, through February 2015.

In exchange, Medtronic will make a one-time payment to Bovie of $750,000. Terms also include a provision for a possible OEM contract manufacturing relationship between Bovie and Salient. The company already has OEM contract manufacturing agreement with Medtronic for advanced electrosurgical generators.